CU23970B1 - DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLE - Google Patents

DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLE

Info

Publication number
CU23970B1
CU23970B1 CU2008000179A CU20080179A CU23970B1 CU 23970 B1 CU23970 B1 CU 23970B1 CU 2008000179 A CU2008000179 A CU 2008000179A CU 20080179 A CU20080179 A CU 20080179A CU 23970 B1 CU23970 B1 CU 23970B1
Authority
CU
Cuba
Prior art keywords
divisible
modified release
allows
active principle
galenic form
Prior art date
Application number
CU2008000179A
Other languages
Spanish (es)
Other versions
CU20080179A7 (en
Inventor
Gilles Fonknechten
Patrick Genty
Jean-Manuel Pean
Patrick Wuthrich
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39796790&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23970(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CU20080179A7 publication Critical patent/CU20080179A7/en
Publication of CU23970B1 publication Critical patent/CU23970B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Una fórmula galénica divisible de liberación modificada de principio activo, donde la forma galénica no subdividida y una fracción de dicha forma obtenida por subdivisión tienen un perfil de disolución idéntico. Medicamentos.A divisible galenic formula of modified release of active ingredient, where the non-subdivided galenic form and a fraction of said form obtained by subdivision have an identical dissolution profile. Medicines.

CU2008000179A 2008-03-21 2008-09-23 DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLE CU23970B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801561A FR2928836B1 (en) 2008-03-21 2008-03-21 SECURE GALENIC FORM FOR MODIFIED RELEASE OF THE ACTIVE INGREDIENT

Publications (2)

Publication Number Publication Date
CU20080179A7 CU20080179A7 (en) 2011-04-26
CU23970B1 true CU23970B1 (en) 2013-12-27

Family

ID=39796790

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2008000179A CU23970B1 (en) 2008-03-21 2008-09-23 DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLE

Country Status (37)

Country Link
US (3) US20090238870A1 (en)
EP (2) EP3025706A1 (en)
JP (2) JP5231906B2 (en)
KR (3) KR20090101048A (en)
CN (1) CN101347414B (en)
AP (1) AP2729A (en)
AR (1) AR067993A1 (en)
AU (1) AU2008207680B8 (en)
BR (1) BRPI0803631A2 (en)
CA (1) CA2629670C (en)
CL (1) CL2008002486A1 (en)
CO (1) CO6020017A1 (en)
CR (2) CR10317A (en)
CU (1) CU23970B1 (en)
EA (1) EA200801862A1 (en)
EC (1) ECSP088727A (en)
FR (1) FR2928836B1 (en)
GT (1) GT200800163A (en)
HK (1) HK1127280A1 (en)
HN (1) HN2008001466A (en)
IL (1) IL193611A0 (en)
JO (1) JO3052B1 (en)
MA (1) MA31218B1 (en)
ME (1) ME01031B (en)
MX (1) MX2008011579A (en)
MY (1) MY150660A (en)
NI (1) NI200800256A (en)
NZ (1) NZ570715A (en)
PE (1) PE20090991A1 (en)
SA (1) SA08290555B1 (en)
SG (1) SG155819A1 (en)
SV (1) SV2008003023A (en)
TW (1) TWI396561B (en)
UA (1) UA86731C2 (en)
UY (1) UY31307A1 (en)
WO (1) WO2009125087A1 (en)
ZA (1) ZA200807354B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2389666T3 (en) 2005-09-09 2012-10-30 Angelini Labopharm, Llc Trazodone composition for once-daily administration
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TR201103946A1 (en) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Glyclazide formulations for controlled release.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ITFI20130184A1 (en) * 2013-08-01 2015-02-02 Valpharma Internat S P A PHARMACEUTICAL FORMULATION OF GLYCLAZIDE WITH MODIFIED RELEASE, ADMINISTRABLE BY ORAL ROUTE, AND ITS PRODUCTION METHOD.
CN106892856A (en) * 2017-02-06 2017-06-27 山东科源制药股份有限公司 A kind of preparation method of gliclazide crude product recrystallization
AU2021237693A1 (en) 2020-03-16 2022-09-08 Grünenthal GmbH Scored tablet

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH069375A (en) * 1992-04-10 1994-01-18 Takeda Chem Ind Ltd Dividable connected tablet
DE4229085C2 (en) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Elongated, divisible tablet
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
EA003101B1 (en) * 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Biphasic controlled release delivery system for high solubility pharmaceuticals and method
JP2006052230A (en) * 1998-04-03 2006-02-23 Kyowa Hakko Kogyo Co Ltd Dividable tablet and press-through pack
EP0947188B1 (en) * 1998-04-03 2008-03-05 Kyowa Hakko Kogyo Co., Ltd. Dividable tablet and press-through pack
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DE10117208A1 (en) * 2001-04-06 2002-10-10 Wolff Walsrode Ag Process for the preparation of low-viscosity, aqueous cellulose ether solutions
CN1294908C (en) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 Oral gliclazide sustained release formulation
JP2007534704A (en) * 2004-04-29 2007-11-29 美時化学製薬股▲ふん▼有限公司 Oral sustained release tablet composition and method for producing the same
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
WO2006061697A1 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
DE102005014141B4 (en) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablet-shaped delayed-release preparation against dizziness
EP1868587A2 (en) * 2005-04-08 2007-12-26 Abbott Laboratories Pharmaceutical formulations comprising fenofibric acid and/or its salts
JP5046501B2 (en) * 2005-08-18 2012-10-10 帝人ファーマ株式会社 Tablets that hold multiple drugs separately
CA2619744C (en) * 2005-08-18 2014-09-02 Teijin Pharma Limited Formulation having accurate dose-dividing function
ES2389666T3 (en) * 2005-09-09 2012-10-30 Angelini Labopharm, Llc Trazodone composition for once-daily administration
JOP20180109A1 (en) * 2005-09-29 2019-01-30 Novartis Ag New Formulation
CN102813635A (en) * 2006-08-10 2012-12-12 武田药品工业株式会社 Pharmaceutical composition
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
JP2008208078A (en) * 2007-02-27 2008-09-11 Takada Seiyaku Kk Tablet to be scored

Also Published As

Publication number Publication date
GT200800163A (en) 2010-05-21
JP5231906B2 (en) 2013-07-10
HN2008001466A (en) 2011-04-25
CO6020017A1 (en) 2009-03-31
WO2009125087A1 (en) 2009-10-15
KR20090101048A (en) 2009-09-24
CN101347414A (en) 2009-01-21
CN101347414B (en) 2011-11-23
US20090238870A1 (en) 2009-09-24
KR20150035829A (en) 2015-04-07
UY31307A1 (en) 2008-10-31
CA2629670A1 (en) 2008-10-01
EP2103302A1 (en) 2009-09-23
MA31218B1 (en) 2010-03-01
SA08290555B1 (en) 2011-07-20
TW200940109A (en) 2009-10-01
NI200800256A (en) 2010-02-11
EA200801862A1 (en) 2009-10-30
AU2008207680B8 (en) 2010-05-13
CU20080179A7 (en) 2011-04-26
CR10317A (en) 2008-11-26
MX2008011579A (en) 2009-09-21
JP2009227651A (en) 2009-10-08
IL193611A0 (en) 2009-08-03
ME01031B (en) 2012-10-20
KR101693189B1 (en) 2017-01-05
US20140221449A1 (en) 2014-08-07
CR20140334A (en) 2014-08-20
FR2928836B1 (en) 2011-08-26
ZA200807354B (en) 2008-11-26
AR067993A1 (en) 2009-10-28
AU2008207680A1 (en) 2009-10-08
CA2629670C (en) 2012-04-17
FR2928836A1 (en) 2009-09-25
BRPI0803631A2 (en) 2011-03-29
TWI396561B (en) 2013-05-21
JO3052B1 (en) 2017-03-15
SG155819A1 (en) 2009-10-29
UA86731C2 (en) 2009-05-12
CL2008002486A1 (en) 2008-12-26
SV2008003023A (en) 2010-07-29
JP2010209103A (en) 2010-09-24
AP2008004614A0 (en) 2008-10-31
HK1127280A1 (en) 2009-09-25
PE20090991A1 (en) 2009-07-18
MY150660A (en) 2014-02-14
NZ570715A (en) 2010-10-29
ECSP088727A (en) 2008-10-31
US20130295176A1 (en) 2013-11-07
AP2729A (en) 2013-08-31
EP3025706A1 (en) 2016-06-01
AU2008207680B2 (en) 2010-04-22
KR20110112266A (en) 2011-10-12

Similar Documents

Publication Publication Date Title
CU23970B1 (en) DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLE
CL2014003306A1 (en) Oral pharmaceutical preparation comprising a bruton tyrosine kinase inhibitor and crystalline form thereof.
CL2015000893A1 (en) Formulation of a solid rapid disintegration pharmaceutical form comprising functionalized calcium carbonate, an active ingredient and at least one disintegrant; and method for its manufacture.
CY1119798T1 (en) FORM IV IV Hydrochloride Ibabradine
IT1400982B1 (en) TRANS-EPITHELIAL OSMOTIC COLLIRIUM FOR THE CARE OF THE KERATOCONO.
EA201201263A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
EA201201202A1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANE EXTILE
BRPI1014583A2 (en) heterocyclic sulfonamides, pharmaceutical compositions and uses thereof.
CR20120316A (en) PROCESSES FOR THE MANUFACTURE OF A PHARMACEUTICALLY ACTIVE AGENT
BR112012028788A2 (en) manufacture of granules without assets
BR112016007414A2 (en) method of producing a monolayer tablet, and monolayer tablet
UY34786A (en) PROCEDURE FOR THE MANUFACTURE OF A PHARMACEUTICAL FORM INCLUDING NIFEDIPINO AND CANDESARTAN CILEXETILO
BR112012024428A2 (en) fast dissolving pharmaceutical composition
CL2009000904A1 (en) Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
CO6592109A2 (en) New crystalline form of a cyclopropylbenzamide derivative
CL2013001684A1 (en) Pharmaceutical composition for oral administration comprising alisporivir, a lipophilic component, a surfactant and a hydrophilic component.
BRPI0921225A2 (en) medicine box and its use.
BRPI0920878A2 (en) ksp161 inhibitor to increase apoptosis, its administration and its use.
CY1118277T1 (en) STABLE PHARMACEUTICAL FORM PEXIGANANIS
UY34189A (en) FUNGICIDE BLENDS THAT INCLUDE ISOXAZOL AND OTHER ACTIVE INGREDIENT.
BR112014032501A2 (en) compound and pharmaceutical composition.
DK2268287T3 (en) DOSAGE SYSTEMS OF ANTITUMUM AGENT, INCLUDING DEOXYCYTIDE INGREDIENT
AR094627A1 (en) CRYSTAL FORMS OF DIHYDROPIRIMIDINE DERIVATIVES

Legal Events

Date Code Title Description
FG Grant of patent